MedTrace Logo

Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

NCT02689986 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2017-01-09

No results posted yet for this study

Summary

Prospective, non-randomized multicenter study on the safety and efficacy of combination therapy with bendamustine and rituximab for chronic cold agglutinin disease.

Conditions

  • Cold Agglutinin Disease
  • Autoimmune Hemolytic Anemia

Interventions

DRUG

Bendamustine, Rituximab

Bendamustine, Rituximab

Sponsors & Collaborators

  • Helse Fonna

    lead OTHER

Principal Investigators

  • Sigbjorn Berentsen, MD, PhD · Department of Research and Innovation, Haugesund Hospital

  • Markku Oksman, MD · Turku University Hospital, Turku, Finland

  • Henrik Birgens, MD, PhD · Herlev University Hospital, Copenhagen, Denmark

  • Geir E Tjonnfjord, MD, PhD · Oslo University Hospital, Oslo, Norway

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Denmark
  • Finland
  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02689986 on ClinicalTrials.gov